Articles

Latest news and updates about the Medicare and pharmacy industries.

What GERs Mean For Pharmacies

Posted on in Industry Updates by Amplicare Team

In recent months, generic effective rate (GER) clauses in pharmacy contracts have taken center stage as pharmacists become more aware of what exactly this means for them. Though not new, in recent years, GERs have become tighter and more restrictive, leading to the potential for unexpectedly high clawbacks by PBMs at the end of a contract year. Such clauses have shown up in several contracts so far this year, indicating a trend which pharmacists would do well to pay attention to.

As contracts are typically brokered between PSAOs and PBMs, not every pharmacy is or will be affected by GERs. With that in mind, here’s what you need to know about GERs and how they can affect your business.

What Exactly are GERs?

A GER is a contractual rate where the full cost (reimbursement plus copay) of all generic drugs over a certain time frame should equal a certain percentage of AWP. Often worded as “effective rate guarantees,” the clause exists to enforce stability around the reimbursements pharmacies will see during the year and prevent them from being over — or under-reimbursed. When a pharmacy receives a reimbursement that is higher than the contracted GER, the PBM will adjust the reimbursements, either at point-of-sale on future claims or at remittance, to match the contracted rate.

GERs are typically expressed as average wholesale price (AWP) minus a percentage and can be calculated either at the point of sale or retroactively. To calculate your current standing over the contract year in relation to the contracted GER, divide the full cost of the billed medications (sum of your reimbursement + copays) by the sum of the medications’ AWP. The resulting number is expressed as a percentage. This is the percentage of AWP you are paid. If the percentage is 15%, your estimated GER is AWP minus 85%.

In the point-of-sale model, the reimbursement amount is calculated upfront to be equal to the contracted GER. Reimbursements may fluctuate from month to month as the PBM attempts to “maintain” the rate. In some cases they also apply a retroactive true-up if unable to maintain the rate at point of sale.

The retroactive model is applied to the total number of generic drugs dispensed over a given period of time. While both follow the same formula, the retroactive model makes it much more difficult to identify underwater claims or claims on which you may be losing money on an ongoing basis.

It is important to note that some contracts calculate the GER on a PSAO-level while others may do it at the individual store and/or claim level. In the former case, individual pharmacies may not be able to ascertain their standing against the reimbursement rates, but they may still be affected by clawbacks. Pharmacies here will have to connect with their PSAOs for more information on standings as the formula above will not apply.

What You Can Do

Unlike DIR fees, GERs cannot be mitigated by a pharmacy’s performance measures. This means that determining GER is considerably more complicated and less straightforward since you lose the ability to influence and improve performance measures to increase profitability. However, there are steps you can take to understand your options and stay ahead:

  1. Talk to your PSAO to ensure you’re aware of which contracts your pharmacy has with a GER. This is the best way to determine if GERs will affect you since your PSAO will often negotiate contracts on your behalf. Understanding the terms of your contract is the first step to getting in front of any unanticipated true-up. Plus, your PSAO or other organizations may have guidelines or tools in place to help pharmacies navigate these rates.
  2. For any plans with a retroactive GER, run an analysis using the formula above on a quarterly basis throughout the year to determine if a clawback is coming and the anticipated size of it.
  3. Some pharmacies have separate inventories for plans with GERs, which can be helpful in alleviating their impact. Typically, they will source different inventory with higher AWPs to help lessen the potential clawback.

Other Articles

Posted on by Amplicare Team

May 10: List Prices Coming to TV Drug Ads, Telehealth Changes to MA Plans Could Save Enrollees Millions, and More

CMS finalizes a rule to include list prices in TV drug ads, Medicare Advantage beneficiaries could save millions thanks...
Continue Reading

Posted on by Amplicare Team

May 3: The Value of OTCs to Healthcare, The Rising Cost of Specialty Drugs, and More

The value of OTCs to healthcare, the rise of specialty drug spending in Medicare Part D, CMS to test...
Continue Reading

Posted on by Amplicare Team

April 26: FDA Approves First Generic Naloxone Nasal Spray, Medicare and Social Security Are On Shaky Ground, And More

The FDA grants final approval to the first generic naloxone nasal spray, Medicare and Social Security face uncertain financial...
Continue Reading

Posted on by admin

April 19: Measles Outbreak Is Going Strong, U.S. Officials Award $350 Million for Opioid Research, and More

The measles outbreak is still going strong, U.S. officials are awarding $350 million for research toward ending the opioid...
Continue Reading